Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 relative bioavailability and food-effect study of VX-152 and ivacaftor formulations in healthy adults
NL-OMON43101Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in cystic fibrosis (CF) comparing Part A: VX-152 formulations with Part B: ivacaftor formulations (2 arms). Started Apr 2016; status: active, not recruiting.
02
Drugs
VX-152ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON43101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43101.